Although it is unclear to what degree cardiac arrhythmias might have played a role in the mortality shown in the meta-analysis of rosiglitazone trials [4], the changes we observed in cardiomyocyte potassium channel expression raise some concerns. The gene discussed is KCNA3; the disease is chronic obstructive pulmonary disease.